104 related articles for article (PubMed ID: 38868222)
1. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
Meng J; Jiang A; Lu X; Gu D; Ge Q; Bai S; Zhou Y; Zhou J; Hao Z; Yan F; Wang L; Wang H; Du J; Liang C
Imeta; 2023 Nov; 2(4):e147. PubMed ID: 38868222
[TBL] [Abstract][Full Text] [Related]
2. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
[TBL] [Abstract][Full Text] [Related]
3. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
Front Immunol; 2022; 13():861328. PubMed ID: 35479084
[TBL] [Abstract][Full Text] [Related]
5. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
6. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
[TBL] [Abstract][Full Text] [Related]
9. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy.
Zhong W; Li Y; Yuan Y; Zhong H; Huang C; Huang J; Lin Y; Huang J
Front Cell Dev Biol; 2021; 9():736540. PubMed ID: 34631713
[TBL] [Abstract][Full Text] [Related]
11. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
12. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
13. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
14. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.
Jiang A; Pang Q; Gan X; Wang A; Wu Z; Liu B; Luo P; Qu L; Wang L
Cancer Innov; 2022 Aug; 1(2):146-167. PubMed ID: 38090653
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
[No Abstract] [Full Text] [Related]
17. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
[TBL] [Abstract][Full Text] [Related]
19. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.
Hong Y; Lv Z; Xing Z; Xu H; Chand H; Wang J; Li Y
Front Pharmacol; 2024; 15():1325447. PubMed ID: 38375034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
